3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
8
Thoracic
3
Gastrointestinal
3
Sarcoma
2
Head & Neck
2
Genitourinary
2
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
9
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Melanoma
4
Head and Neck Neoplasms
4
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Neoplasms
1
Mesothelioma, Malignant
1
Lung Neoplasms
1
Hypersensitivity
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
1
Interventions
Paclitaxel
26
pembrolizumab
24
Docetaxel
20
Capecitabine
19
Fulvestrant
17
Trastuzumab
16
Anastrozole
15
Cyclophosphamide
14
Lapatinib
13
Letrozole
11
Carboplatin
11
Radiotherapy
10
Doxorubicin
10
palbociclib
9
Therapeutics
9
Nivolumab
9
Exercise
9
Gemcitabine
8
Cisplatin
8
Blood Specimen Collection
8
Tamoxifen
7
Bevacizumab
7
liposomal doxorubicin
6
exemestane
6
abemaciclib
6
Vinorelbine
6
Standard of Care
6
Fluorouracil
6
atezolizumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Immune Checkpoint Inhibitors
×
Breast
×
Clear all
NCT05716295
2024-05-08
ORCHID-1
Medikine, Inc.
Phase 1/2
Terminated
26 enrolled